Conmed (CNMD) Misses Q4 EPS by 1c; Guidance Misses
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
CONMED (CNMD) PT Raised to $56 at Summer Street Post Q4
January 28, 2015 8:18 AM ESTSummer Street analyst Mark Landy reiterated a Buy rating and boosted his price target on CONMED (NASDAQ: CNMD) to $56.00 (from $46.00)
Landy commented, "Yesterday CNMD reported 4Q14 revenues in line with the January 14 preannouncement. Revenues and EPS were $195MM and $0.53, respectively. As CNMD carries meaningful FX hedges, given its outsized exposure to international markets (~50%... More
